AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
11.68
-0.23 (-1.93%)
Nov 6, 2025, 11:38 AM EST - Market open
AngioDynamics Revenue
AngioDynamics had revenue of $75.71M in the quarter ending August 31, 2025, with 12.18% growth. This brings the company's revenue in the last twelve months to $300.72M, up 2.73% year-over-year. In the fiscal year ending May 31, 2025, AngioDynamics had annual revenue of $292.50M, down -3.76%.
Revenue (ttm)
$300.72M
Revenue Growth
+2.73%
P/S Ratio
1.62
Revenue / Employee
$445,508
Employees
675
Market Cap
481.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 292.50M | -11.42M | -3.76% |
| May 31, 2024 | 303.91M | -34.84M | -10.28% |
| May 31, 2023 | 338.75M | 22.53M | 7.13% |
| May 31, 2022 | 316.22M | 25.21M | 8.66% |
| May 31, 2021 | 291.01M | 26.85M | 10.17% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANGO News
- 9 days ago - AngioDynamics to Participate in the UBS Global Healthcare Conference - Business Wire
- 24 days ago - AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List - Business Wire
- 4 weeks ago - AngioDynamics: Discounted Sales Multiple With Real Growth Engines - Seeking Alpha
- 5 weeks ago - AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results - Benzinga
- 5 weeks ago - AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum - Business Wire
- 5 weeks ago - Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings - Benzinga
- 7 weeks ago - AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025 - Business Wire